JP2015516813A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516813A5 JP2015516813A5 JP2015509207A JP2015509207A JP2015516813A5 JP 2015516813 A5 JP2015516813 A5 JP 2015516813A5 JP 2015509207 A JP2015509207 A JP 2015509207A JP 2015509207 A JP2015509207 A JP 2015509207A JP 2015516813 A5 JP2015516813 A5 JP 2015516813A5
- Authority
- JP
- Japan
- Prior art keywords
- activatable antibody
- egfr
- seq
- cancer
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 238000010494 dissociation reaction Methods 0.000 claims description 5
- 230000005593 dissociations Effects 0.000 claims description 5
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical group CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 3
- 102000001301 EGF receptor Human genes 0.000 claims 34
- 108060006698 EGF receptor Proteins 0.000 claims 34
- 239000003795 chemical substances by application Substances 0.000 claims 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 108091005804 Peptidases Proteins 0.000 claims 10
- 239000004365 Protease Substances 0.000 claims 10
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 10
- 102000004190 Enzymes Human genes 0.000 claims 9
- 108090000790 Enzymes Proteins 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 8
- 125000006850 spacer group Chemical group 0.000 claims 6
- 239000000758 substrate Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 206010014733 Endometrial cancer Diseases 0.000 claims 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 201000000062 kidney sarcoma Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- -1 chromophore Substances 0.000 claims 3
- 239000002872 contrast media Substances 0.000 claims 3
- 239000000975 dye Substances 0.000 claims 3
- 239000007850 fluorescent dye Substances 0.000 claims 3
- 239000012216 imaging agent Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229910021645 metal ion Inorganic materials 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000000873 masking effect Effects 0.000 claims 2
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 claims 1
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical group CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 claims 1
- 101500021165 Aplysia californica Myomodulin-A Proteins 0.000 claims 1
- 108010053070 Glutathione Disulfide Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical group C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
- 229930195731 calicheamicin Natural products 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical group CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical group COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 1
- 229960005501 duocarmycin Drugs 0.000 claims 1
- 229930184221 duocarmycin Natural products 0.000 claims 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 claims 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims 1
- 108700026078 glutathione trisulfide Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 21
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 21
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 241000894007 species Species 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639796P | 2012-04-27 | 2012-04-27 | |
| US61/639,796 | 2012-04-27 | ||
| US201261662204P | 2012-06-20 | 2012-06-20 | |
| US61/662,204 | 2012-06-20 | ||
| US201361749220P | 2013-01-04 | 2013-01-04 | |
| US61/749,220 | 2013-01-04 | ||
| US201361749529P | 2013-01-07 | 2013-01-07 | |
| US61/749,529 | 2013-01-07 | ||
| US201361763237P | 2013-02-11 | 2013-02-11 | |
| US61/763,237 | 2013-02-11 | ||
| PCT/US2013/038540 WO2013163631A2 (en) | 2012-04-27 | 2013-04-26 | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019017216A Division JP2019108331A (ja) | 2012-04-27 | 2019-02-01 | 上皮成長因子受容体を結合する活性化可能抗体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015516813A JP2015516813A (ja) | 2015-06-18 |
| JP2015516813A5 true JP2015516813A5 (enExample) | 2017-10-12 |
Family
ID=49484042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509207A Pending JP2015516813A (ja) | 2012-04-27 | 2013-04-26 | 上皮成長因子受容体を結合する活性化可能抗体及びその使用方法 |
| JP2019017216A Pending JP2019108331A (ja) | 2012-04-27 | 2019-02-01 | 上皮成長因子受容体を結合する活性化可能抗体及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019017216A Pending JP2019108331A (ja) | 2012-04-27 | 2019-02-01 | 上皮成長因子受容体を結合する活性化可能抗体及びその使用方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US9120853B2 (enExample) |
| EP (1) | EP2841093A4 (enExample) |
| JP (2) | JP2015516813A (enExample) |
| KR (1) | KR102138743B1 (enExample) |
| CN (2) | CN104540518A (enExample) |
| AU (2) | AU2013251310B2 (enExample) |
| BR (1) | BR112014026354A2 (enExample) |
| CA (1) | CA2871458C (enExample) |
| CO (1) | CO7160045A2 (enExample) |
| HK (1) | HK1204581A1 (enExample) |
| IL (2) | IL235331A0 (enExample) |
| IN (1) | IN2014MN02164A (enExample) |
| MX (1) | MX2014013041A (enExample) |
| PE (1) | PE20150605A1 (enExample) |
| PH (1) | PH12014502641B1 (enExample) |
| RU (1) | RU2713121C2 (enExample) |
| SG (1) | SG11201406943XA (enExample) |
| WO (1) | WO2013163631A2 (enExample) |
| ZA (2) | ZA201407715B (enExample) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010081173A2 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| CA2754072C (en) | 2009-03-02 | 2019-01-15 | Massachusetts Institute Of Technology | Methods and products for in vivo enzyme profiling |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| AU2013251310B2 (en) | 2012-04-27 | 2018-02-15 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| CN112162094A (zh) * | 2013-01-04 | 2021-01-01 | 西托姆克斯治疗公司 | 用于检测生物系统中的蛋白酶活性的组合物和方法 |
| WO2014152199A1 (en) * | 2013-03-15 | 2014-09-25 | Abbvie Inc. | Antibody drug conjugate (adc) purification |
| EP3003370B1 (en) | 2013-05-28 | 2020-01-22 | Dcb-Usa Llc | Antibody locker for the inactivation of protein drug |
| JP6847660B2 (ja) | 2013-06-07 | 2021-03-24 | マサチューセッツ インスティテュート オブ テクノロジー | リガンドをコードする合成バイオマーカーのアフィニティベースの検出 |
| WO2015000062A1 (en) * | 2013-07-05 | 2015-01-08 | Avidbiologics Inc. | Egfr antibody conjugates |
| CA2918795A1 (en) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| IL291329B1 (en) | 2013-09-25 | 2025-09-01 | Cytomx Therapeutics Inc | Polypeptides that can be determined in matrix metalloproteinases and uses thereof |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
| CN106459153B (zh) | 2014-01-31 | 2021-12-21 | 西托姆克斯治疗公司 | 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法 |
| LT3137595T (lt) | 2014-04-29 | 2019-06-25 | Novartis Ag | Naujos stuburinių ląstelės ir dominančio polipeptido rekombinantinės raiškos būdai |
| WO2016014974A2 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| CN104910275A (zh) * | 2014-12-04 | 2015-09-16 | 上海张江生物技术有限公司 | 一种新型抗表皮生长因子受体抗体、其制备方法及用途 |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| MX2017011644A (es) * | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| AU2016258988A1 (en) * | 2015-05-04 | 2017-12-07 | Cytomx Therapeutics, Inc | Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof |
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 |
| AU2016257929B2 (en) * | 2015-05-04 | 2022-10-20 | Cytomx Therapeutics, Inc | Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof |
| CN111234027A (zh) | 2015-05-21 | 2020-06-05 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| US20160362469A1 (en) * | 2015-06-12 | 2016-12-15 | Tianxin Wang | Methods for protein modification in pharmaceutical applications |
| WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| US10822419B2 (en) | 2015-06-26 | 2020-11-03 | University Of Southern California | Masking chimeric antigen receptor T cells for tumor-specific activation |
| WO2017019729A1 (en) | 2015-07-27 | 2017-02-02 | The General Hospital Corporation | Antibody derivatives with conditionally enabled effector function |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| CN105399830B (zh) * | 2015-09-08 | 2019-11-19 | 北京天广实生物技术股份有限公司 | 抗egfr人源化单克隆抗体、其制备方法及用途 |
| CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药（上海）有限公司 | 可活化的嵌合受体 |
| EA039736B1 (ru) * | 2015-09-15 | 2022-03-04 | Сайтомкс Терапьютикс, Инк. | Анти-pdl1-антитела, активируемые анти-pdl1-антитела и способы их применения |
| CA3002674A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| MX2018005348A (es) | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para transduccion de tumores. |
| AU2016358296B2 (en) | 2015-11-19 | 2020-05-21 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| CN108697798A (zh) * | 2016-02-16 | 2018-10-23 | 达纳-法伯癌症研究所有限公司 | 免疫疗法组合物及方法 |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| US11448643B2 (en) | 2016-04-08 | 2022-09-20 | Massachusetts Institute Of Technology | Methods to specifically profile protease activity at lymph nodes |
| WO2017193070A1 (en) | 2016-05-05 | 2017-11-09 | Massachusetts Institute Of Technology | Methods and uses for remotely triggered protease activity measurements |
| KR102584340B1 (ko) | 2016-11-03 | 2023-10-10 | 브리스톨-마이어스 스큅 컴퍼니 | 활성화가능한 항-ctla-4 항체 및 그의 용도 |
| CN110036034A (zh) | 2016-12-09 | 2019-07-19 | 西雅图遗传学公司 | 卷曲螺旋掩蔽的二价抗体 |
| AU2018231127A1 (en) * | 2017-03-09 | 2019-09-19 | Cytomx Therapeutics, Inc. | CD147 antibodies, activatable CD147 antibodies, and methods of making and use thereof |
| AU2018248327B2 (en) | 2017-04-07 | 2024-10-10 | Massachusetts Institute Of Technology | Methods to spatially profile protease activity in tissue and sections |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| US11220544B2 (en) | 2017-07-14 | 2022-01-11 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
| WO2019018828A1 (en) * | 2017-07-20 | 2019-01-24 | Cytomx Therapeutics, Inc. | METHODS OF QUALITATIVE AND / OR QUANTITATIVE ANALYSIS OF ACTIVATABLE ANTIBODY PROPERTIES AND USES THEREOF |
| US11623965B2 (en) | 2017-08-16 | 2023-04-11 | Bristol-Myers Squibb Company | Prodruggable antibodies, prodrugs thereof, and methods of use and making |
| MX2020002667A (es) | 2017-09-08 | 2020-08-03 | Maverick Therapeutics Inc | Proteinas de unión condicionalmente activadas restringidas. |
| UA129446C2 (uk) | 2017-10-13 | 2025-04-30 | Гарпун Терап'Ютікс, Інк. | Триспецифічні білки і способи їх застосування |
| IL321773A (en) | 2017-10-14 | 2025-08-01 | Cytomx Therapeutics Inc | Activatable antibodies and methods for preparing them |
| WO2019113386A1 (en) * | 2017-12-07 | 2019-06-13 | Janux Therapeutics, Inc. | Modified bispecific t cell receptors |
| MX2020006297A (es) | 2017-12-15 | 2020-12-07 | Aleta Biotherapeutics Inc | Variantes de cd19. |
| MX2020008289A (es) | 2018-02-08 | 2020-09-25 | Genentech Inc | Moleculas biespecificas de union al antigeno y metodos de uso. |
| US11054428B2 (en) | 2018-03-05 | 2021-07-06 | Massachusetts Institute Of Technology | Inhalable nanosensors with volatile reporters and uses thereof |
| EP3769309A1 (en) | 2018-03-20 | 2021-01-27 | Cytomx Therapeutics Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| WO2019222282A1 (en) * | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| WO2019222283A1 (en) | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
| MX2020012252A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina 12 activables y metodos de uso de los mismos. |
| CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| WO2020068920A2 (en) | 2018-09-25 | 2020-04-02 | Massachusetts Institute Of Technology | Lung protease nanosensors and uses thereof |
| CA3120327A1 (en) | 2018-12-06 | 2020-06-11 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| US11153281B2 (en) | 2018-12-06 | 2021-10-19 | Bank Of America Corporation | Deploying and utilizing a dynamic data stenciling system with a smart linking engine |
| EP3911753A1 (en) | 2019-01-17 | 2021-11-24 | Massachusetts Institute of Technology | Sensors for detecting and imaging of cancer metastasis |
| CN120484127A (zh) | 2019-03-05 | 2025-08-15 | 武田药品工业有限公司 | 受约束的条件性活化的结合蛋白 |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| US20230220105A1 (en) * | 2019-06-06 | 2023-07-13 | Janux Therapeutics, Inc. | Tumor activated t cell engagers and methods of use thereof |
| WO2020251878A1 (en) | 2019-06-11 | 2020-12-17 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| WO2021061867A1 (en) * | 2019-09-23 | 2021-04-01 | Cytomx Therapeutics, Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
| WO2021097376A1 (en) | 2019-11-14 | 2021-05-20 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| BR112022011357A2 (pt) | 2019-12-13 | 2022-08-23 | Genentech Inc | Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo |
| CN114945597A (zh) * | 2020-01-17 | 2022-08-26 | 艾提欧生物疗法有限公司 | 降低脱靶毒性的前抗体 |
| AU2021208642B2 (en) * | 2020-01-17 | 2025-06-05 | Immunelogic Therapeutics, Inc. | Pro-antibody that reduces off-target toxicity |
| JP2024518539A (ja) | 2020-04-04 | 2024-05-01 | ジャナックス セラピューティクス，インク． | 抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法 |
| KR20220166814A (ko) * | 2020-04-09 | 2022-12-19 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 항체를 함유하는 조성물 |
| ES3040950T3 (en) * | 2020-08-11 | 2025-11-06 | Janux Therapeutics Inc | Cleavable linker compositions and methods |
| MX2023006817A (es) | 2020-12-09 | 2023-08-14 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras. |
| AU2022367525A1 (en) | 2021-10-15 | 2024-05-02 | Amgen Inc. | Activatable polypeptide complex |
| WO2023064955A1 (en) | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex |
| US20230183382A1 (en) | 2021-10-15 | 2023-06-15 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex |
| JP2025507294A (ja) * | 2022-02-04 | 2025-03-18 | ザイトックス セラピューティクス アクチボラゲット | Ｅｇｆｒ結合ドメインとマスキングドメインとを含む融合タンパク質 |
| CA3247048A1 (en) | 2022-04-13 | 2023-10-19 | Genentech Inc | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE |
| TW202532442A (zh) * | 2022-08-31 | 2025-08-16 | 中國醫藥大學 | 抗meEGFR抗體、其抗原結合片段及其用途 |
| WO2025235515A1 (en) | 2024-05-07 | 2025-11-13 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex formulations |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| WO1988001513A1 (fr) | 1986-08-28 | 1988-03-10 | Teijin Limited | Complexe d'anticorps cytocide et procede de production |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| EP1295952A3 (en) | 1996-01-23 | 2003-07-09 | The Board of Trustees of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
| GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
| TW505653B (en) | 1996-02-26 | 2002-10-11 | Meiji Seika Co | Triterpene derivatives possessing an effect of treating liver diseases and pharmacentical compositions containing the same |
| CA2265454A1 (en) | 1996-09-09 | 1998-03-19 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
| CA2405550A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1286700A2 (en) * | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| AU9399501A (en) | 2000-10-09 | 2002-04-22 | Isis Innovation | Therapeutic antibodies |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| US6989452B2 (en) * | 2001-05-31 | 2006-01-24 | Medarex, Inc. | Disulfide prodrugs and linkers and stabilizers useful therefor |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| US20040111757A1 (en) * | 2002-12-05 | 2004-06-10 | Dongxiao Zhang | Multiplex system for production and screening of monoclonal antibodies |
| US8088387B2 (en) * | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| AR048098A1 (es) * | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| AU2006284651C1 (en) | 2005-08-31 | 2013-09-12 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| CA2645347A1 (en) * | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| HRP20140172T1 (hr) | 2006-05-30 | 2014-03-28 | Genentech, Inc. | Protutijela i imunokonjugati kao i njihove uporabe |
| CA2654000A1 (en) | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| WO2008101177A2 (en) * | 2007-02-16 | 2008-08-21 | University Of Virginia Patent Foundation | Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis |
| EP2170960B1 (en) | 2007-07-13 | 2015-07-29 | Bac Ip B.V. | Single-domain antigen-binding proteins that bind mammalian igg |
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
| DE112008003232T5 (de) * | 2007-11-30 | 2011-02-24 | Glaxo Group Limited, Greenford | Antigen-Bindungskonstrukte |
| ES2544971T3 (es) | 2008-05-13 | 2015-09-07 | Genentech, Inc. | Análisis de conjugados de fármacos y anticuerpos mediante espectrometría de masas con captura por afinidad basada en esferas |
| US8895702B2 (en) * | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| EP2356131A4 (en) * | 2008-12-08 | 2012-09-12 | Tegopharm Corp | MASKING LIGANDS FOR REVERSIBLE INHIBITION OF VERSATILE COMPOUNDS |
| US20110178279A1 (en) | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
| WO2010081173A2 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| IL300733B1 (en) * | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| US9193791B2 (en) | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| CA2849705A1 (en) | 2011-09-23 | 2013-03-28 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Modified albumin-binding domains and uses thereof to improve pharmacokinetics |
| AU2013251310B2 (en) | 2012-04-27 | 2018-02-15 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| EP3003387A1 (en) | 2013-06-04 | 2016-04-13 | Cytomx Therapeutics Inc. | Compositions and methods for conjugating activatable antibodies |
| CA2918795A1 (en) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
-
2013
- 2013-04-26 AU AU2013251310A patent/AU2013251310B2/en not_active Ceased
- 2013-04-26 PE PE2014001901A patent/PE20150605A1/es active IP Right Grant
- 2013-04-26 US US13/872,052 patent/US9120853B2/en active Active
- 2013-04-26 CA CA2871458A patent/CA2871458C/en not_active Expired - Fee Related
- 2013-04-26 RU RU2014147684A patent/RU2713121C2/ru active
- 2013-04-26 CN CN201380033414.8A patent/CN104540518A/zh active Pending
- 2013-04-26 HK HK15105286.5A patent/HK1204581A1/xx unknown
- 2013-04-26 BR BR112014026354A patent/BR112014026354A2/pt not_active IP Right Cessation
- 2013-04-26 KR KR1020147032521A patent/KR102138743B1/ko not_active Expired - Fee Related
- 2013-04-26 CN CN201910284451.5A patent/CN110078827A/zh active Pending
- 2013-04-26 IN IN2164MUN2014 patent/IN2014MN02164A/en unknown
- 2013-04-26 MX MX2014013041A patent/MX2014013041A/es active IP Right Grant
- 2013-04-26 WO PCT/US2013/038540 patent/WO2013163631A2/en not_active Ceased
- 2013-04-26 SG SG11201406943XA patent/SG11201406943XA/en unknown
- 2013-04-26 JP JP2015509207A patent/JP2015516813A/ja active Pending
- 2013-04-26 EP EP13780884.6A patent/EP2841093A4/en not_active Withdrawn
-
2014
- 2014-10-23 ZA ZA2014/07715A patent/ZA201407715B/en unknown
- 2014-10-26 IL IL235331A patent/IL235331A0/en active IP Right Grant
- 2014-10-27 CO CO14237235A patent/CO7160045A2/es unknown
- 2014-11-26 PH PH12014502641A patent/PH12014502641B1/en unknown
-
2015
- 2015-07-31 US US14/815,111 patent/US9545442B2/en active Active
- 2015-10-21 ZA ZA2015/07859A patent/ZA201507859B/en unknown
-
2016
- 2016-12-16 US US15/381,972 patent/US9889211B2/en active Active
-
2018
- 2018-01-19 US US15/875,947 patent/US10709799B2/en active Active
- 2018-05-10 AU AU2018203262A patent/AU2018203262A1/en not_active Abandoned
-
2019
- 2019-02-01 JP JP2019017216A patent/JP2019108331A/ja active Pending
- 2019-04-02 IL IL265788A patent/IL265788A/en unknown
-
2020
- 2020-06-04 US US16/892,973 patent/US11890354B2/en active Active
-
2023
- 2023-12-26 US US18/396,187 patent/US20240398998A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516813A5 (enExample) | ||
| JP7073487B2 (ja) | 操作された抗体化合物およびこれらの抱合体 | |
| RU2014147684A (ru) | Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения | |
| JP2025063090A (ja) | マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 | |
| JP2023159099A (ja) | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 | |
| JP6835586B2 (ja) | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 | |
| CN106536553B (zh) | 生长和分化因子15(gdf-15)的单克隆抗体及其治疗癌性恶病质和癌症的用途 | |
| RU2011133819A (ru) | Композиции модифицированных антител, способы их получения и применения | |
| US20100189727A1 (en) | Masking Ligands For Reversible Inhibition Of Multivalent Compounds | |
| JP2012514982A5 (enExample) | ||
| JP2022523200A (ja) | 活性化可能な免疫チェックポイント阻害剤とコンジュゲートされた活性化可能な抗体の組み合わせ療法 | |
| WO2021183717A1 (en) | Proteinaceous therapeutics | |
| KR20140104944A (ko) | 항-ａｘｌ 항체 및 그의 용도 | |
| CN105744944B (zh) | 免疫系统调节器 | |
| KR20140071501A (ko) | Ｓｐａｒｃ 결합 ｓｃｆｖｓ | |
| CA2793647A1 (en) | Prophylaxis of colorectal and gastrointestinal cancer | |
| WO2011135040A1 (en) | Fluorescent antibody fusion protein, its production and use | |
| EP2267125B1 (en) | Cancer cell migration and cancer cell invasion inhibitor | |
| CN106279404A (zh) | 一种可溶且稳定的异质二聚tcr | |
| EP1956032B1 (en) | Monoclonal antibody directed against cd166 and method for production thereof | |
| CN117279941A (zh) | Vegfa结合分子 | |
| CN114025795B (zh) | 使用靶向her2的双特异性抗原结合构建体治疗胆道癌的方法 | |
| CN117510642A (zh) | 一种全基因编码的双靶向嵌合体及其应用 | |
| CN112823168A (zh) | 结合her2的四聚体多肽 | |
| WO2022105922A1 (zh) | 源自于ssx2抗原的短肽 |